Print

responsif GmbH Release: Cancer Researchers At An University In Stockholm, Sweden, And Biotechnology Experts In Erlangen, Germany, Join Forces To Fight Cancer 
10/19/2005 5:10:28 PM

The German biotechnology company responsif GmbH and scientists from a prestigious University in Stockholm, Sweden have recently signed a Cooperation Agreement which will bring a promising new treatment for cancer one step closer to clinical trials. The Swedish cancer researchers working in the Dept. of Oncology & Pathology in the Section for Experimental Oncology are now using an “anchoring” technique developed by responsif to pack tumour antigens into virus capsoids; the aim is to create an anti-tumour vaccine which will mobilise the body’s own immune defences against cancer cells.
//-->